AusBiotech is pleased to announce that Dr Megan Baldwin, CEO and Managing Director of Opthea Limited, has been appointed as AusBiotech’s new Deputy Chair, following Michelle Burke becoming the Chair in late February.
Dr Baldwin has been a Director of AusBiotech since December 2017. As CEO of Opthea, a biotech company developing OPT-302 for the treatment of retinal eye diseases, she is actively engaged in the biotech sector and drug development. Dr Baldwin’s experience spans over 20 years in research and development of oncology and ophthalmic therapies, having worked in both Melbourne and San Francisco in academic and commercial roles. She holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research and is a member of the Australian Institute for Company Directors.
Dr Megan Baldwin says, “I am delighted to take on the role of Deputy Chair, AusBiotech, and to have this opportunity to work closely with Michelle, Lorraine and fellow members of AusBiotech’s Board of Directors. AusBiotech is at the forefront of representing the biotech sector in Australia and in these challenging times, it is more important than ever to have an organisation bringing together the various facets of the industry and positioning the sector for success. I look forward to continuing to work with the AusBiotech in this new role.”
Michelle Burke, Chair, AusBiotech, says, “We are very fortunate to have Megan’s experience, passion and commitment to help drive the strategic direction of AusBiotech; the Board is pleased to welcome Megan to her new Deputy Chair role.”
Prof Jan Tennent, Founder and Principal Advisor of ConnectBio, has also recently been appointed as Chair of AusBiotech’s Remuneration and Nomination Committee. Jan was appointed as a Director of AusBiotech in October 2017 and brings extensive experience in research translation and commercialisation to her roles. Jan is a senior executive with international and national experience in the pharmaceutical, agribio and medical research sectors.